Jun. 18, 2022
sudapyridine (WX-081)
oral ATP-synthase inhibitor Ph. I candidate for pulmonary tuberculosis toxicol. risk mitigation from prev. disclosed inhibitor Bioorg. Med. Chem. Lett., Sep 1, 2022 WuXi AppTec, Shanghai, CN
oral ATP-synthase inhibitor Ph. I candidate for pulmonary tuberculosis toxicol. risk mitigation from prev. disclosed inhibitor Bioorg. Med. Chem. Lett., Sep 1, 2022 WuXi AppTec, Shanghai, CN